Yazar "Yilmaz N." için listeleme
-
One-Third of European Patients With Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment
Ørnbjerg L.M.; Rugbjerg K.; Georgiadis S.; Rasmussen S.H.; Lindström U.; Pavelka K.; Yilmaz N. (Journal of Rheumatology, 2023)Objective. To investigate the distribution of patient-reported outcomes (PROs) in patients with axial spondyloarthritis (axSpA) initiating a tumor necrosis factor inhibitor (TNFi), to assess the proportion reaching PRO ... -
Salivary and Serum B-cell activating factor (BAFF) levels after hydroxychloroquine treatment in primary Sjögren's syndrome
Mumcu G.; Biçakçigil M.; Yilmaz N.; Ozay H.; Karaçayli Ü.; Cimilli H.; Yavuz S. (Quintessence Publishing Co., Ltd, 2013)Purpose: Some evidence implicates a role of hydroxychloroquine (HQ) in the management of Sjögren's syndrome. This study evaluated the effect of HQ on saliva B-cell activating factor (BAFF) levels as well as health related ... -
Two-year experience with mycophenolate mofetil in patients with scleroderma lung disease: A case series
Yilmaz N.; Can M.; Kocakaya D.; Karakurt S.; Yavuz S. (Blackwell Publishing, 2014)To assess the effect of mycophenolate mofetil (MMF) on pulmonary functions in patients with systemic sclerosis-associated lung disease (SSc-ILD) who experienced an inadequate response to first line cyclophosphamide (CYC) ...
